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The massive and irrational use of antibiotics in livestock productions has fostered the
occurrence and spread of resistance to “old class antimicrobials.” To cope with that
phenomenon, some regulations have been already enforced in the member states
of the European Union. However, a role of livestock animals in the relatively recent
alerts on the rapid worldwide increase of resistance to last-choice antimicrobials
as carbapenems is very unlikely. Conversely, these antimicrobials are increasingly
administered in veterinary hospitals whose role in spreading bacteria or mobile genetic
elements has not adequately been addressed so far. A cross-sectional study was carried
out on 105 hospitalized and 100 non-hospitalized pets with the aim of measuring the
prevalence of carbapenem-resistant Gram-negative bacteria (GNB) colonizing dogs and
cats, either hospitalized or not hospitalized and estimating the relative odds. Stool
samples were inoculated on MacConkey agar plates containing 1 mg/L imipenem
which were then incubated aerobically at 37◦C ± 1 for 48 h. Isolated bacteria
were identified first by Matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry and were confirmed by 16S rRNA sequencing. The genetic basis of
resistance was investigated using PCR methods, gene or whole genome sequencing
(WGS). The prevalence of pets harboring carbapenem-resistant bacteria was 11.4
and 1.0% in hospitalized and not-hospitalized animals, respectively, with an odds
ratio of 12.8 (p < 0.01). One pet carried two diverse isolates. Overall, 14 gram-
negative non-fermenting bacteria, specifically, one Acinetobacter radioresistens, five
Acinetobacter baumannii, six Pseudomonas aeruginosa and two Stenotrophomonas
maltophilia were isolated. The Acinetobacter species carried acquired carbapenemases
genes encoded by blaNDM−1 and blaOXA−23. In contrast, Pseudomonas phenotypic
resistance was associated with the presence of mutations in the oprD gene. Notably,
inherent carbapenem-resistant isolates of S. maltophilia were also resistant to the
first-line recommended chemotherapeutic trimethoprim/sulfamethoxazole. This study
estimates the risk of colonization by carbapenem-resistant non-fermenting GNB in
pets hospitalized in veterinary tertiary care centers and highlights their potential role
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in spreading resistance genes among the animal and human community. Public health
authorities should consider extending surveillance systems and putting the release of
critical antibiotics under more strict control in order to manage the infection/colonization
of pets in veterinary settings.
Keywords: one health, carbapenem resistance, Acinetobacter radioresistens, dogs and cats, hospitalization,
veterinary tertiary care facilities, blaNDM−1, blaOXA−23
INTRODUCTION
Among the large quantities of antimicrobials given to animals
each year, only a fractional amount is reserved to pets
(Guardabassi et al., 2004; European Medicines Agency, 2015).
The latter estimate is expected to be undervalued since injectable
molecules and human specialties are not adequately taken
into account (European Medicines Agency, 2015). Even more
interesting, it is the qualitative point of view; indeed, whereas
in husbandry almost exclusively “old class antibiotics” are
used; in veterinary tertiary care facilities (VTCF) for pets,
also antimicrobials critically important for human medicine
as carbapenems are administered in certain critical cases. In
humans, Enterobacteriaceae and non-fermenting gram-negative
bacteria (GNB) Pseudomonas aeruginosa, Acinetobacter spp.
and Stenotrophomonas maltophilia account for the majority of
the pandemic carbapenem resistance threat. The occurrence of
carbapenem-resistant bacteria in veterinary medicine has already
been brought to the attention of the scientific community due to
the severe impact that this phenomenon may cause (Endimiani
et al., 2011; Shaheen et al., 2013; Stolle et al., 2013). Resistant
organisms are transmitted among pets, owners and veterinary
staff and, in this way, spread to the community. (Boerlin et al.,
2001; Guardabassi et al., 2004; Leite-Martins et al., 2014; Yao et al.,
2016).
To date, the assessment of public health risk posed by
VTCFs has not adequately been addressed and only scarce but
relevant information is available (Boerlin et al., 2001; Pulss
et al., 2018). Certainly, veterinary hospitals share some risk
factors with human hospitals, such as the use of antibiotics,
complex treatments, prolonged hospitalization of critically ill or
immunocompromised patients, and the presence of intensive
care units. These factors favor nosocomial infections, and
the exchange of antimicrobial-resistant bacteria and genetic
determinants of resistance (Poirel et al., 2008). In human
hospitals, a particular concern has recently arisen, based on the
evidence that the spread of resistant bacteria is not restricted
to clonal outbreaks but also due to asymptomatic carriage
(Cerqueira et al., 2017).
With the aim to refine the focus of antibiotic resistance in
pets hospitalized in VTCFs, a cross-sectional study was thus
carried out to investigate the prevalence of carbapenem-resistant
GNB in pets admitted to VTCFs. To this aim, dogs and cats
admitted to two different VTCFs in the Bologna area (Northern
Italy) were included. In addition, privately owned pets living in
the same area and not hospitalized were also investigated and
compared in order to assess the relative odds of being colonized
after hospitalization.
MATERIALS AND METHODS
Experimental Design and Animals
This cross-sectional study was carried out within the Bologna
area from November 2014 to January 2015. Feces from 105
hospitalized pets (61 dogs and 44 cats) and 100 non-hospitalized
pets (73 dogs and 27 cats) were collected. Hospitalized pets
from two different facilities, both of which were characterized by
the presence of intensive care units and referral practices, were
included consecutively after at least 48 h of hospitalization. The
non-hospitalized pets were from 100 distinct owners, had never
been hospitalized and had not been given antibiotics for at least 2
months; they will hereafter be defined as “general population.”
All the private owners of the animals considered in this study
signed an informed consent form to authorize the rectal swab
sampling.
Isolation and Identification of Enteric
Bacteria
Rectal swabs were used for collecting the fecal material
from the pets and were immediately placed in the transport
medium Cary-Blair Medium (Oxoid). Within 24 h, the
swabs were soaked in 1 mL of sterile saline, vortexed,
and 0.1 mL was inoculated on plates of MacConkey Agar
(Oxoid) containing 1 mg/L imipenem (Sigma-Aldrich).
The plates were incubated aerobically at 37◦C ± 1 for
48 h.
All the different morphotypes of colonies grown in the same
plate were subcultivated to obtain pure culture. Isolates were
identified firstly by Matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (bioMérieux) and successively
confirmed by partial sequencing of the 16S rRNA gene (Brosius
et al., 1978).
Antimicrobial Susceptibility
For all isolates, the minimum inhibitory concentrations
(MICs) of imipenem and meropenem was determined
using E-test strips (bioMérieux) following manufacturer
instructions. P. aeruginosa, S. maltophilia, and Acinetobacter
spp. were considered resistant to imipenem and meropenem
at values ≥ 8 mg/L as suggested by the EUCAST (2016).
The MIC of colistin were determined by broth microdilution
using a breakpoint > 2 mg/L (EUCAST, 22 march 2016).
Disk diffusion was used for testing all other antibiotics
(Supplementary Material) and interpreted according to Clinical
and Laboratory Standards Institute standard (CLSI 2014
M100-S24).
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Molecular Characterization of
Antimicrobial Resistance
The isolates were screened for the presence of the following
genes coding for carbapenem-hydrolyzing enzymes: blaVIM,
blaNDM−1, blaIMP, blaKPC, and blaOXA−48−like using a
multiplex polymerase chain reaction (PCR) assay as previously
described (Doyle et al., 2012). In addition, a real-time
PCR was used for detecting blaOXA−23 (Supplementary
Material) followed by direct Sanger sequencing of the
amplicons as a confirmatory assay. The presence of AmpC
was carried out using a previously described multiplex PCR
(Pérez-Pérez and Hanson, 2002) while extended-spectrum
β-lactamases (ESBL) genes were detected using a multiplex
PCR with subsequent melt curve analysis suitable to identify
blaSHV, blaTEM , and blaCTX−M gene targets (Supplementary
Material).
Two PCR reactions were used to confirm the presence
of chromosomally encoded metallo β-lactamases (MBL) in
S. maltophilia (Supplementary Material); in particular, two
PCR assays were carried out targeting an internal sequence
of the L1 gene and a sequence located within the region
bridging the transcription factor encoding gene ampR and the
inducible β-lactamase L2 gene (Gould et al., 2006; Okazaki and
Avison, 2008). Furthermore, trimethoprim/sulfamethoxazole
(SXT) resistance was investigated using primers pairs for sul1,
sul2, and dfrA genes as well as class 1, 2, and 3 integrons (Hu
et al., 2011; Supplementary Material).
To investigate whether blaNDM−1 was located in transposon
Tn125, a PCR was carried out at 5′ terminus with primers
fwd_ISAba125 and NDM-reverse and at the 3′ terminus of the
transposon with the fwd primer annealing on F_1pac _and
rev_ISAba125 (Supplementary Material). Finally, the oprD gene
of P. aeruginosa was amplified using outer primers, amplifying
the almost complete sequence of the gene followed by sequencing
of the amplicon by internal primers (Supplementary Material).
Whole Genome Sequencing
Since, to the best of our knowledge, Acinetobacter radioresistens
carrying chromosomally encoded blaNDM−1 has not previously
been reported, the whole genome of the isolate was sequenced to
better characterize the resistance pattern. Also the five isolates of
A. baumannii were fully sequenced to characterize the blaOXA−23
genetic environment, the complete resistome profile and to
assess the Multi Locus Sequence Type as well as the clonal
relationship. For Whole Genome Sequencing (WGS), genomic
DNA was extracted from overnight broth culture in Brain
Heart Infusion (Oxoid, Basingstoke, United Kingdom) using the
MagAttract HMW DNA kit (Qiagen, Milan, Italy). The DNA
samples were quantified with a fluorescent nucleic acid dye
(Picogreen; Invitrogen, Paisley, United Kingdom), and libraries
were prepared using the Nextera XT DNA Sample Preparation
Kit (Illumina, Inc., San Diego, CA, United States). Sequencing
was carried out on an Illumina MiSeq platform with 2 × 250 bp
paired-end runs. The sequence quality of the reads was evaluated
using FastQC (Andrews, 2016). The reads were assembled with
SPAdes 3.7.1. The ResFinder web server1 using a threshold of
100% identity for the genes encoding β-lactamases and 98%
identity for all other genes and CARD2 (Jia et al., 2017) using
the Resistance Gene Identifier v 4.0.2 were used to search for
antimicrobial resistance genes in the Acinetobacter spp. draft
genomes.
MLST
The Sequence Type of A. baumannii isolates was inferred
from assembled contigs using the Multi Locus Sequence Typing
application 1.8 (Assembled Genomes/Contigs) (Larsen et al.,
2012).
In addition, to further analyze the genetic relatedness of the
apparently clonal A. baumannii isolates, an alternative approach
to the MLST, the wgMLST was carried out by genome-wide gene-
by-gene comparisons of a dataset of 5633 genes retrieved from
the whole genome assemblies using the Bionumerics 7.6 package
software (Applied Maths) using either an assembly free and an
assembly based algorithm in Bionumerics engine calculation. The
isolate 92A IMI was assumed as index isolate for comparison.
The results were graphed as dendrogram with percentage of
homology (Supplementary Figure S1).
PFGE Typing
For clonality assessment, A. baumannii isolates were typed using
a rapid PFGE protocol with ApaI (40 U/plug) (Promega) as a
restriction enzyme according to Durmaz (Durmaz et al., 2009).
Nucleotide Accession Number
The raw sequence data of Acinetobacter radioresistens and of
five Acinetobacter baumannii isolates were deposited in the
GenBank database under BioProject accession PRJNA344732 and
PRJNA437120, respectively.
RESULTS
Thirteen out of 205 pets carried carbapenem-resistant bacteria
with a prevalence estimate of 6.3% [95% confidence interval (CI):
3.4–10.6%]. Of these, 12 (8 dogs and 4 cats) were hospitalized
pets [prevalence estimate 11.4% (95% CI: 6.0–19.1%)] and 1
dog was from the general population [prevalence estimate 1.0%
(95% CI: 0.0–5.4%)]. The odds ratio of the hospitalized pets
was 12.8 (95% CI: 1.6–100.2; p < 0.01). In one hospitalized
cat, two different carbapenem-resistant bacteria were isolated;
therefore, 14 isolates were found in total. They included one
Acinetobacter radioresistens, five A. baumannii, six P. aeruginosa,
and two S. maltophilia (Supplementary Table S1). The MICs of
imipenem for the Acinetobacter species ranged from 16 mg/L to
more than 32 mg/L, for the P. aeruginosa they were 16 mg/L and
for the S. maltophilia they were> 32 mg/L (Table 1). All bacteria
showed multiple resistance, however, in all cases, the bacteria
were susceptible to colistin (MIC < 2 mg/L). Carbapenemase
resistance genes were detected in all isolates except P. aeruginosa.
1www.genomicepidemiology.org
2https://card.mcmaster.ca
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TABLE 1 | Characteristics of the isolates resistant to carbapenems obtained from feces of dogs and cats.
Isolate Organism MIC of
imipenem
(mg/L)
MIC of
meropenem
(mg/L)
Resistance determinant Dog/Cat
(source)
Hospitalized
Carpapem-resistance Other β-lactamases
1A IMI Acinetobacter radioresistens >32 >32 blaNDM-1 blaOXA-23 Dog Yes
87A IMI Acinetobacter baumannii (ST2) >32 >32 blaOXA-23 blaOXA-66,blaTEM, AmpC Cat Yes
92A IMI Acinetobacter baumannii (ST2) 16 >32 blaOXA-23 blaOXA-66,blaTEM, AmpC Dog Yes
108A IMI Acinetobacter baumannii (ST2) 16 >32 blaOXA-23 blaOXA-66,blaTEM, AmpC Cat Yes
115A IMI Acinetobacter baumannii (ST2) >32 >32 blaOXA-23 blaOXA-66,blaTEM, AmpC Dog Yes
213A IMI Acinetobacter baumannii (ST2) 16 >32 blaOXA-23 blaOXA-66,blaTEM, AmpC Cat∗ Yes
3 A IMI Pseudomonas aeruginosa 16 8 oprD blaSHV AmpC Dog Yes
110A IMI Pseudomonas aeruginosa 16 4 oprD blaSHV CTX-M Dog Yes
111A IMI Pseudomonas aeruginosa 16 8 ND blaSHV Dog Yes
117A IMI Pseudomonas aeruginosa 16 2 oprD blaTEM Dog Yes
121A IMI Pseudomonas aeruginosa 16 4 oprD AmpC Dog Yes
131A IMI Pseudomonas aeruginosa 16 8 ND blaSHV AmpC Cat Yes
207A IMI Stenotrophomonas maltophilia >32 >32 L1 Dog No
213B IMI Stenotrophomonas maltophilia >32 >32 L1 Cat∗ Yes
MIC, Minimum Inhibitory Concentration; ND, not determined; ST, Sequence type (Pasteur scheme). ∗ Indicates the same animal.
A. radioresistens carried both blaNDM−1 and blaOXA−23. The
blaNDM−1 gene was chromosomally located and organized in a
composite transposon encompassing blaNDM−1, bleMBL, trpF,
tat, cutA1, groES, groEL, insE, and1pac genes bracketed between
a pair of ISAba125. The presence of a mobile element with
IS elements was further confirmed by a specific PCR assay
designed to investigate the genetic environment of blaNDM−1
gene (Figure 1).
The blaOXA−23 lacked ISAba1, ISAba4 (Turton et al., 2006;
Corvec et al., 2007; Poirel et al., 2008; Karthikeyan et al.,
2010; Smet et al., 2012) or ISAcsp2 (Poirel et al., 2012)
upstream insertion sequences according to ISfinder3. These IS
sequences are known to provide the effective promoter to the
hydrolyzing enzyme encoding gene blaOXA−23 in A. baumannii
for an elevated level of expression (Turton et al., 2006). Other
genetic determinants of resistance included aminoglycoside
resistance encoding genes strA [aph(3′′)-ib] and strB [aph(6)-1d],
sulphonamide resistance gene sul2, bleomycin resistant protein
BRP and tetracycline resistance gene tet.
The A. radioresistens whole genome was sequenced, and the
reads showed a coverage of 293X and a guanine-cytosine (GC)
content of 42%. The assembled genome encountered 81 contigs
with N50 of 113445 and mean contig size of 38028.383 bp. The
genome length was 3.080 Mbp.
All the A. baumannii strains carried both intrinsic blaOXA−66
and acquired blaOXA−23 Class D Oxacillinases. However, while
blaOXA−23 was embedded in a transposon bracketed within two
ISAba1 insertion sequence which provide a strong promoter
leading to a sustained expression of oxacillinase hydrolyzing
enzyme, the blaOXA−66 lacks an upstream IS sequence (Figure 2).
Additionally, besides oxacillinases, other β-lactamases
were present in all isolates of A. baumannii. Acinetobacter
3www-is.biotoul.fr
derived cephalosporinase blaADC−73 (AmpC allele 20) with
an upstream ISAba1 in the promoter region and a likely
sustained expression was present. Furthermore, A. baumannii
isolates carried blaTEM−1D embedded in a single copy IS26-
blaTEM−1D-Tn3-IS26, likely responsible for the sulbactam
resistance phenotype (Krizova et al., 2013; Yang et al.,
2018).
Overall, the antimicrobial resistance profile of the five
A. baumannii isolates showed an extensively drug-resistant
(XDR) phenotype, i.e., non-susceptibility to at least one agent
in all but two or fewer antimicrobial categories (Supplementary
Table S2; Magiorakos et al., 2012). The comprehensive resistance
determinants are enlisted in Supplementary Table S3.
The two S. maltophilia isolates carried inducible chromosomal
encoded L1 metallo-β-lactamase with carbapenem hydrolyzing
activity and its regulatory element ampR (Gould et al., 2006;
Okazaki and Avison, 2008). Notably, both S. maltophilia isolates
were resistant to SXT due to the presence of both sul1 and sul2
genes associated with class 1 integron mobile element.
Finally, carbapenem-resistant P. aeruginosa were negative to
carbapenemase genes but carried either blaSHV, and/or blaTEM ,
and/or blaCTX−M β-lactamase associated with an oprD gene with
truncating mutations in 4 out of 6 of these isolates (Tables 1, 2).
All A. baumannii strains showed the same macrorestriction
profile by PFGE (Supplementary Figure S2). All isolates were
assigned to ST2 (Pasteur’s scheme) or ST451 (Oxford’s scheme).
Using the complete panel of the coded alleles a UPGMA tree
was calculated in Bionumerics 7.6 software (Supplementary
Figure S1). The wgMLST showed that all isolates except one were
closely related with homology > 99.8%. (<6 diverse allele). The
only isolate 108A IMI seemed more dissimilar with an homology
of 98.8%. The most closely related isolates were sampled on the
same day (87A IMI and 92A IMI) or 2 months apart (115A IMI
and 213A IMI) (Supplementary Figure S1).
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FIGURE 1 | Acinetobacter radioresistens blaNDM−1 genetic environment. The schematic presentation of the A. radioresistens blaNDM−1 transposon Tn125
encompassing blaNDM−1, bleMBL, trpF, tat, cutA1, groES, groEL, insE, and 1pac genes bracketed between a pair of ISAba125 is drawn above. Red rectangles
indicate the position of the amplicons.
FIGURE 2 | Acinetobacter baumannii blaOXA−23 genetic environment. The schematic presentation of the A baumannii blaOXA−23 transposon Tn2006 encompassing
blaOXA−23, and few ORFs bracketed between ISAba1 colored in yellow. Flanking ORFs are colored in purple.
TABLE 2 | oprD mutations in Pseudomonas aeruginosa isolates resistant to carbapenems.
Isolate oprD mutation Resulting change in the protein
3A IMI c.604ins (IS256 family transposase ISPa1328) Protein truncated
110A IMI c.840_854delGGGCGCGTATACCCTinsCGGC Frameshift and premature stop codon; Predicted protein of 313 aa
111A IMI c.875 T > C p.292P > L
117A IMI c.970delA Frameshift and premature stop codon; Predicted protein of 344 aa
121A IMI c.1244G > A Nonsense mutation and premature stop codon; Predicted protein of 414 aa
131A IMI c.154G > A; c.397A > C; p.52D > N p.132K > Q
Strain used for comparison: P. aeruginosa ATCC 27853 (GenBank Accession Number KF649209.1). Missense mutations with respect to the reference strain are indicated
only in those isolates without truncating mutations.
DISCUSSION
This study findings focuses on Acinetobacter spp. as the
main emerging threat to public health associated with the
hospitalization in VTCFs. Notably, we identified for the first
time to the best of our knowledge, a carbapenem resistant
A. radioresistens isolate carrying a blaNDM−1 gene within a Tn125
mobile element. The same composite Tn125 has already been
reported in other Acinetobacter species (Pfeifer et al., 2011;
Bonnin et al., 2012; Dortet et al., 2012; Fu et al., 2012; Chatterjee
et al., 2016) but not yet in A. radioresistens. The presence of a
Class B MBL in a mobile element is a concern since it could
be readily transferred to other bacteria residing in the intestine,
such as Enterobacteriaceae. Its potential to serve as a reservoir for
worldwide dissemination of blaNDM should be given outstanding
attention and should not be undervalued in view of the fact that
was isolated in a veterinary and not human tertiary care settings.
Conversely, A. radioresistens was found to carry
blaOXA−23 without ISAb1 sequences and, as a consequence,
the hydrolyzing oxacillinase was not expressed at high
level. Overall, A. radioresistens was multi-drug resistant
being not susceptible to quinolones, tetracycline and
trimethoprim/sulfamethoxazole though it remained susceptible
to amikacin and gentamicin, which are not affected by
Aminoglycoside O-phosphotransferases strA and strB, as
well as to ampicillin/sulbactam and colistin.
Noteworthy, the resistome of the five A. baumannii isolates
showed an XDR phenotype (Supplementary Table S2) including
non-susceptibility to quinolones, gentamicin, amikacin and
sulbactam with only colistin as putative effective treatment.
It is worth mentioning that also 16S rRNA methylase gene
armA recently reported in nosocomial outbreaks in Italy
and responsible for resistance to aminoglycosides including
gentamicin and amikacin, was found (Brigante et al., 2012). For
these features, the A. baumannii isolates represent an actual
hazard retaining high epidemic potential.
A. baumannii is reported as a frequent cause of nosocomial
infections with increased mortality worldwide (Higgins et al.,
2010). Very recently, single cases and small case series of
clinical isolates of carbapenem resistant A. baumannii of different
sequence types and carrying blaOXA−23 were reported (Pomba
et al., 2014; Ewers et al., 2016, 2017; Lupo et al., 2017).
Those authors focused the attention on companion animals as
potential public health hazard. Also a remarkably high rate of
asymptomatic pet carriers of carbapenem-resistant A. baumannii
ST25 (2.7%) has been reported in France and pointed out pets as
possible reservoir of community acquired infections (Hérivaux
et al., 2016).
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All the A. baumannii isolates in VTCFs in our study belong
to ST2. In Italy, besides, the endemic so called “Italian strain”
ST78, the ST2 strains belonging to International Clonal lineage
II has progressively become dominant as a cause of epidemic
outbreaks in hospitals and is even replacing the ST78 strains.
Both strains share great ability to adhere to cells, to invade
and survive within pneumocytes as well as to form biofilm on
abiotic surface (Ambrosi et al., 2017) hence, replacing of the
ST78 may be associated with the acquisition of ST2 strains of
highly expressed blaOXA−23 oxacillinase (D’Arezzo et al., 2011;
Brigante et al., 2012; Mezzatesta et al., 2012). Indeed, in last
years, nosocomial outbreaks in Italy are almost all ascribed to ST2
blaOXA−23 producing strains (Carretto et al., 2011; Agodi et al.,
2014; Principe et al., 2014; Perilli et al., 2015; Piana et al., 2015).
BlaOXA−23 producing strains were not reported in a survey,
which had investigated nosocomial A. baumannii isolated in 2007
in the Bologna Area, while they were reported in another survey
carried out later in 2011 (Carretto et al., 2011; Principe et al.,
2014).
Within-hospital selective pressure clearly plays a role in
favoring the emergence of MDR but there is also inter-hospital
interconnection modalities (i.e., patients transfer) which explains
the simultaneous outbreaks of related resistant A. baumannii
strains (Karkada et al., 2011). How the VTCFs/ICUs fit in this
model is far from being understood but the evidence that the
strains isolated in veterinary and human medical settings in the
same geographical area worth to be examined as well as the role
of the community.
When investigating the clonal relatedness, all A. baumannii
isolates showed the same PFGE pattern. Also wgMLST confirmed
the high relatedness of at least of four of five of the
isolates whereas one isolate showed less similarity, however, the
complexity in interpreting the genomic variability is challenging,
since no threshold guidelines could be applied and a case-by-case
interpretation is still used in this matter (Halachev et al., 2014;
Higgins et al., 2017; Shaheen et al., 2018); Since this study did
not deal with an epidemic outbreak, the A. baumannii isolates
found during the survey may represent the genetic evolution
over time of originally the same clone which has colonized the
medical environment for its ability to grow on abiotic surface,
has accumulated genetic variations making it to diverge from the
original clone. Eventually, the knowledge of the frequency rate of
mutation accumulation in A. baumannii would lead to infer the
precise time of colonization.
Unlike Acinetobacter isolates, P. aeruginosa-associated
carbapenem resistance is linked to the loss of oprD (Lee and
Ko, 2012; Ocampo-Sosa et al., 2012; Kim et al., 2016) and it
is associated with multidrug resistance. In most of our cases,
the loss of oprD was caused by different mutations within the
gene causing a premature stop codon as a consequence of a
large insertion, a frameshift or a nonsense mutation. The loss of
oprD was also associated with either ESBL (blaSHV, blaTEM or
blaCTX−M) or AmpC resistance genes. The presence of different
mutations and β-lactamase genes indirectly demonstrates the
lack of clonal relatedness at least between the P. aeruginosa
isolates. The absence of clonal spread in apparent pseudo-
outbreaks is very frequent for Gram-negative non-fermenting
bacteria and it is correlated to their ability to colonize the
medical device and surface (Valdezate et al., 2004) and produce
multispecies biofilms (Tan et al., 2017).
Together with Acinetobacter spp. and P. aeruginosa,
other carbapenemase-resistant non-fermenter GNB, namely
S. maltophilia, were found. S. maltophilia is not an inherently
primary pathogen, but it is rather environmental bacteria
intrinsically resistant to β-lactams including carbapenems due
to inducible β-lactamase (Gould et al., 2006; Okazaki and
Avison, 2008). It should be noted that, in S. maltophilia human
nosocomial infections, the antibiotic of choice for treatment of
infections caused by these bacteria is SXT (Madi et al., 2016).
Our isolates actually showed complete resistance to SXT. Both
sul1 associated with class 1 integron, and sul2 genes were found
in the isolates. Plasmid-mediated sul1 and sul2 are responsible
for the worldwide emergence of resistance to sulfonamides
reported beginning since 2007 (Toleman et al., 2007). In 2009,
a comprehensive meta-analysis carried out on 3872 strains,
found 4% of SXT resistant strains (Looney et al., 2009). As far
as we know, the only report from southern Europe, namely
from Greece, showed that the majority of S. maltophilia clinical
isolates were sensitive to SXT (Samonis et al., 2012) while most
of the concerns were from Middle east (Turkey, Iran) and Far
East (Korea and China) (Liaw et al., 2010). The origin of this
resistance at the genetic level was ascribed to sul genes. In
particular, the presence of sul2 is reported in isolates showing
very high resistance to SXT (Toleman et al., 2007). However,
sul genes alone do not confer trimethoprim resistance but
certainly, they are frequently associated with dfrA genes in the
gene cassettes of the integrons. In our isolates, dfrA genes were
not found and the high resistance to SXT was not clarified.
Furthermore, class 1 integrons may carry genes coding for
tolerance to common disinfectants and facilitate the horizontal
spread of resistance to other bacterial species. Overall, these
features make these opportunistic pathogens isolated in this
study an insidious threat.
On a more general note, the findings of the study show
that hospitalization in VTCFs providing cures to pets represents
a significant risk factor of colonization with carbapenem
resistant GNB embodying the most significant current hazard
to public health in VTCFs. These findings are even more
worrying if compared with those found in human hospitals
in very similar cross-sectional epidemiological survey during
non-epidemic outbreaks. The carbapenemase producing GNB
was 0.4% compared with the 6% of this study and the overall
prevalence of carbapenem-resistant GNB was 4.8% compared
with the 11.4% of this study (Pantel et al., 2015). The other
side of the coin, thankfully, is that the more pathogenic
Enterobacteriaceae carrying carbapenemase resistance genes
reported to cause epidemic cases around the world and also
recently found in Germany in many different veterinary hospitals
(Pulss et al., 2018) were not found in these veterinary healthcare
settings. It should be noted that KPC producers (mainly
Enterobacteriaceae) may exhibit susceptibility to imipenem and
resistance to ertapenem causing an underestimation of their
prevalence using MacConkey supplemented with imipenem
(1 mg/L) as carried out in this study. However, KPC producers
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were not shown either using ceftazidime (1 mg/L) for ESBL
bacteria nor using multiplex PCR directly on the DNA purified
from stools for molecular screening (data not shown).
Non-fermenter GNB may cause nosocomial infections,
particularly in immunocompromised critically ill patients, raising
the mortality rate (Siempos et al., 2010; Chiu et al., 2015).
Furthermore, Acinetobacter spp. and S. maltophilia, but also
P. aeruginosa, show great ability to adapt to any environment,
including hospitals; the clonal relatedness between the isolates
of A. baumannii carried by pets hospitalized in one VTCF
over a short period of time demonstrated the colonization
of the environment. Non-fermenter GNB are also readily
carried on the skin of colonized animals thus enabling the
easy transmission to veterinarians, personnel providing care
and owners as well as other hospitalized pets. These bacteria
represent a rising challenge for healthcare management because
they are frequently multidrug resistant as a consequence of
a multitude of mechanisms. In addition, non-fermenter GNB
may be a source of genes which are carbapenemase resistant
for Enterobacteriaceae (Toleman et al., 2012; Bonnin et al.,
2014). It should be emphasized that non-fermenter GNB
were not isolated in clinical samples, but they colonized
the intestines of the pets; no outbreaks sustained by non-
fermenter GNB were reported in either of the investigated
VTCFs during the period of study and, hence, no awareness of
the risk was evident and no specific measures of control were
activated.
In VTCFs, the concerns of carbapenem resistance should
be even more compelling with respect to human hospitals due
to the extensive, systematic use of broad-spectrum antibiotics,
the relative lack of antimicrobial susceptibility-based therapy,
the objective difficulties in applying and maintaining hygienic
practices and the very limited use of systematic monitoring
programs. In fact, these findings and considerations give rise to
concerns regarding the risk for veterinary personnel veterinary
students or trainees and for the pet owners, highlighting
the possible role that veterinary facilities play in spreading
carbapenemase-resistant genes in the environment, including the
human community.
In the VTCFs investigated in this study, wide spectrum
β-lactam drugs are used as first line therapy in hospitalized dogs.
The consequent high environmental pressure of such antibiotics
represents a risk factor for the co-selection of carbapenem-
resistant bacteria (Maseda et al., 2017). In fact, almost all the
carbapenem-resistant isolates are either Sulbactam resistant or
AmpC or ESBL producers (data not shown), i.e., the “restricted
use” of a specific class of antibiotics is not per se sufficient
to avoid the emergence of the relative resistance. Since it is
evident that carbapenem-resistant gram negative non-fermenters
represent an actual threat in VTCFs, it appears more reasonable
to also extend the public health surveillance system to VTCFs,
and to allow the traceable and targeted use of carbapenems or
other critical antibiotics, such as colistin, to control infection
or to eradicate the carriage of multidrug resistant bacteria in
pets. Appropriate antibiotic stewardships as well as active and
continuous surveillance of resistance should be implemented in
VTCFs which ask to be accredited for the use of carbapenems or
last-choice antimicrobials.
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